Table 2. Comparison of clinical and demographic characteristics, TACPR, and perinatal outcomes in groups based on the clinical severity of ICP.
|
- |
Mild ICP (n=72) |
Severe ICP (n=26) |
p-value* |
|
Age |
28.34±5.44 |
28.92±5.10 |
0.763a |
|
BMI (kg/m2) |
27.73±2.91 |
28.15±2.08 |
0.275a |
|
Gravidity |
2 (2) |
2 (3) |
0.292b |
|
Parity |
0 (1) |
0 (2) |
0.320b |
|
GA at diagnosis (weeks) |
33 (4) |
33 (6) |
0.238b |
|
C-section rates |
29 (40.3%) |
15 (57.7%) |
0.168c |
|
First trimester blood parameters | |||
|
AST (IU/L) |
22.08±7.83 |
31.12±17.24 |
0.020 a |
|
ALT (IU/L) |
28.5 (20.5) |
29 (38) |
0.275b |
|
PLT (109/L) |
254.96±59.98 |
271.48±58.05 |
0.275a |
|
TACPR |
2.26 (2.95) |
3.11 (7.7) |
0.204b |
|
Blood parameters at the diagnosis week | |||
|
AST (IU/L) |
53.5 (58) |
96 (104.5) |
<0.001 b |
|
ALT (IU/L) |
88 (84.25) |
230.84 (227.5) |
<0.001 b |
|
PLT (109/L) |
255 (74) |
265.36±76.82 |
0.971b |
|
TACPR |
17.39 (32.1) |
59.1 (201.27) |
<0.001b |
|
Clinical characteristics | |||
|
Highest SBA concentration (µmol/L) |
19.68±7.08 |
80.70±31.67 |
<0.001 a |
|
Cases treated with UDCA |
56 (77.8%) |
25 (96.2%) |
0.037 c |
|
Dose of UDCA (mg/day) |
750 (187.5) |
750 (250) |
0.002 b |
|
Perinatal outcomes | |||
|
GA at delivery (week) |
37 (1) |
36 (2) |
0.016 b |
|
Preterm birth |
17 (23.6%) |
15 (57.7%) |
0.003 c |
|
Low birth weight (<2500 g) |
11 (15.3%) |
4 (15.4%) |
1.000c |
|
Birth weight (g) |
2952.5±506.42 |
2879.8±461 |
0.430a |
|
APGAR score (1st min.) |
7 (1) |
7 (1) |
0.049 b |
|
APGAR score (5th min.) |
9 (1) |
9 (1) |
0.245b |
|
Meconium-stained amniotic fluid |
3 (4.2%) |
7 (26.9%) |
0.003 c |
|
NICU admission |
10 (13.9%) |
15 (57.7%) |
<0.001 c |
|
Stillbirth |
1 (1.4%) |
1 (3.8%) |
0.462c |
|
CAPO |
14 (19.4%) |
16 (38.5%) |
<0.001 c |
ALT: Alanine transaminase, AST: Aspartate transaminase, BMI: Body mass index, CAPO: Composite adverse perinatal outcomes, GA: Gestational age, ICP: Intrahepatic cholestasis of pregnancy, NICU: Neonatal intensive care unit, PLT: Platelet, SBA: Serum bile acid, TACPR: Transaminase complex-to-platelet ratio, UDCA: Ursodeoxycholic acid
Data Presentation: Values are expressed as mean ± standard deviation for normally distributed continuous variables, median with interquartile range for non-normally distributed data, or count (percentage) for categorical variables.
*Significance levels were assessed using the following tests:a: Independent sample t-test,b: Mann-Whitney U test,c: Fisher’s exact test.
A p-value below 0.05 was regarded as statistically significant. Outcomes meeting this threshold are emphasized in bold.